

**APSAVD-IAS-JAS Joint Symposium to be held in  
The 56<sup>th</sup> Annual Scientific Meeting of  
Japan Atherosclerosis Society**

**(Sponsored by Kowa Company, Ltd.)**

**<<Date, Time, Venue>>**

Date: Sunday, 7th July, 2024,

Time: 2:10pm – 4:00pm JST (Total 110 minutes, with 4 lectures for 20 minutes each and discussion)

Venue: Kobe International Conference Center, Kobe, Japan [No webcast available]

<https://kobe-cc.jp/en/visitors/access/>

**<<Theme>> Cardiovascular Risk Management in Patients with Diabetes**

**<<Co-chairs>>**

[Dr. Richard O'Brien](#) (Immediate Past President of APSAVD / University of Melbourne, Australia)

[Dr. Shizuya Yamashita](#) (Rinku General Medical Center, Japan)

**<<Lecture 1>>**...15-minute lecture + 5-minute Q&A

**“The significance of lipid management in patients with diabetes”**

Topics will include the risk of complications, associations of dyslipidemia with the risks, and the effectiveness of lipid management for high TG and low HDL-C in patients with diabetes, especially for Asian population.

[Dr. Nuntakorn Thongtang](#) (Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand)

(She is the last author of a clinical paper, “Cluster analysis of Thai patients with newly diagnosed type 2 diabetes mellitus to predict disease progression and treatment outcomes: A prospective cohort study” *BMJ Open Diabetes Res Care*. 2022 Dec;10(6):e003145)

**<<Lecture 2>>**...15-minute lecture + 5-minute Q&A

**“The current status of lipid management in patients with diabetes in China”**

Topics will include the epidemiology of diabetic dyslipidemia and the current status of lipid management in patients with diabetes in China in addition to Chinese guideline for

lipid management and may include the data of phase III study of pemafibrate conducted in China if applicable.

**Dr. Peng Daoquan** (The Second Xiangya Hospital of Central South University, China)  
(He is a co-author of “2023 Chinese Guideline for Lipid Management” *Front Pharmacol.* 2023 Aug 29;14:1190934.)

**<<Lecture 3>>**...15-minute lecture + 5-minute Q&A

**“The potential role of Pemafibrate in patients with diabetes”**

Topics will include the relationship between small dense LDL and cardiovascular risk and recent evidence of pemafibrate effect on small dense LDL-C in diabetic patients receiving statin therapy.

**Dr. Yusaku Mori** (Showa University School of Medicine, Japan)

(He is the last author of a clinical paper, “Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.” *J Diabetes Investig.* 2023 Dec;14(12):1401-1411.)

**<<Lecture 4>>**...15-minute lecture + 5-minute Q&A

**“Unmet needs in cardiovascular risk management”**

Topics will include the recent publication named “Pemafibrate Reduces Incidence of Lower Extremity Ischemic Ulcer and Gangrene: Evidence from PROMINENT” presented at the AHA23 congress.

**Dr. Brendan M. Everett** (Brigham and Women's Hospital, U. S.)

(He is a co-author of a clinical paper, “Pradhan AD et al., Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.” *N Engl J Med.* 2022 Nov 24;387(21):1923-1934)

**<<Discussion>>**...20 minutes